Bristol-myers Squibb Co. (BMY)

$58.87

+0.64

(+1.1%)▲

Market is closed - opens 8 PM, 25 Nov 2024
star icon

Bristol-Myers Squibb Co is a biopharmaceutical company that is involved in the development and commercialization of drugs for various diseases.

Performance

  • $57.63
    $58.89
    $58.87
    downward going graph

    2.11%

    Downside

    Day's Volatility :2.13%

    Upside

    0.03%

    downward going graph
  • $39.35
    $61.08
    $58.87
    downward going graph

    33.16%

    Downside

    52 Weeks Volatility :35.58%

    Upside

    3.62%

    downward going graph

Returns

PeriodBristol-myers Squibb Co.Sector (Health Care)S&P500
3 Months
22.04%
-7.3%
5.9%
6 Months
42.75%
-0.2%
12.5%
1 Year
18.31%
9.9%
30.9%
3 Years
3.63%
8.8%
27.0%

Highlights

Market Capitalization
119.4B
Book Value
$8.45
Dividend Share
2.4
Dividend Yield
4.12%
Earnings Per Share (EPS)
-3.58
PEG Ratio
2.03
Wall Street Target Price
59.369
Profit Margin
-15.3%
Operating Margin TTM
18.48%
Return On Assets TTM
6.07%
Return On Equity TTM
-31.33%
Revenue TTM
47.4B
Revenue Per Share TTM
23.41
Quarterly Revenue Growth YOY
8.4%
Gross Profit TTM
36.4B
EBITDA
19.2B
Diluted Eps TTM
-3.58
Quarterly Earnings Growth YOY
-0.36
EPS Estimate Current Year
0.9
EPS Estimate Next Year
7.06
EPS Estimate Current Quarter
1.49
EPS Estimate Next Quarter
1.52

Analyst Recommendation

Hold
    32%Buy
    64%Hold
    3%Sell
Based on 31 Wall street analysts offering stock ratings for Bristol-myers Squibb Co.(by analysts ranked 0 to 5 stars)
Based on 31 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
20
20
19
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 0.85%

Current $58.87
Target $59.37

Company Financials

FY18Y/Y Change
Revenue
22.6B
↑ 8.59%
Net Income
5.0B
↑ 391.76%
Net Profit Margin
21.95%
↑ 17.1%
FY19Y/Y Change
Revenue
26.1B
↑ 15.89%
Net Income
3.4B
↓ 30.55%
Net Profit Margin
13.15%
↓ 8.8%
FY20Y/Y Change
Revenue
42.5B
↑ 62.62%
Net Income
-9.0B
↓ 361.56%
Net Profit Margin
-21.16%
↓ 34.31%
FY21Y/Y Change
Revenue
46.4B
↑ 9.09%
Net Income
7.0B
↓ 177.75%
Net Profit Margin
15.08%
↑ 36.24%
FY22Y/Y Change
Revenue
46.2B
↓ 0.49%
Net Income
6.3B
↓ 9.54%
Net Profit Margin
13.71%
↓ 1.37%
FY23Y/Y Change
Revenue
45.0B
↓ 2.5%
Net Income
8.0B
↑ 26.84%
Net Profit Margin
17.83%
↑ 4.12%
Q2 FY23Q/Q Change
Revenue
11.2B
↓ 0.98%
Net Income
2.1B
↓ 8.36%
Net Profit Margin
18.47%
↓ 1.48%
Q3 FY23Q/Q Change
Revenue
11.0B
↓ 2.32%
Net Income
1.9B
↓ 6.99%
Net Profit Margin
17.58%
↓ 0.89%
Q4 FY23Q/Q Change
Revenue
11.5B
↑ 4.66%
Net Income
1.8B
↓ 8.61%
Net Profit Margin
15.35%
↓ 2.23%
Q1 FY24Q/Q Change
Revenue
11.9B
↑ 3.38%
Net Income
-11.9B
↓ 775.99%
Net Profit Margin
-100.39%
↓ 115.74%
Q2 FY24Q/Q Change
Revenue
12.2B
↑ 2.83%
Net Income
1.7B
↓ 114.1%
Net Profit Margin
13.77%
↑ 114.16%
Q3 FY24Q/Q Change
Revenue
11.9B
↓ 2.53%
Net Income
1.2B
↓ 27.92%
Net Profit Margin
10.18%
↓ 3.59%
FY18Y/Y Change
Total Assets
10.7B
↓ 68.23%
Total Liabilities
7.3B
↓ 66.14%
FY19Y/Y Change
Total Assets
129.9B
↑ 1119.1%
Total Liabilities
78.2B
↑ 964.72%
FY20Y/Y Change
Total Assets
118.5B
↓ 8.82%
Total Liabilities
80.6B
↑ 3.01%
FY21Y/Y Change
Total Assets
109.3B
↓ 7.74%
Total Liabilities
73.3B
↓ 9.05%
FY22Y/Y Change
Total Assets
96.8B
↓ 11.43%
Total Liabilities
65.7B
↓ 10.38%
FY23Y/Y Change
Total Assets
95.2B
↓ 1.72%
Total Liabilities
65.7B
↓ 0.04%
Q2 FY23Q/Q Change
Total Assets
93.5B
↓ 0.84%
Total Liabilities
61.5B
↓ 1.5%
Q3 FY23Q/Q Change
Total Assets
91.3B
↓ 2.38%
Total Liabilities
62.2B
↑ 1.21%
Q4 FY23Q/Q Change
Total Assets
95.2B
↑ 4.27%
Total Liabilities
65.7B
↑ 5.58%
Q1 FY24Q/Q Change
Total Assets
99.0B
↑ 4.07%
Total Liabilities
82.5B
↑ 25.59%
Q2 FY24Q/Q Change
Total Assets
94.6B
↓ 4.43%
Total Liabilities
77.6B
↓ 5.95%
Q3 FY24Q/Q Change
Total Assets
93.7B
↓ 1.03%
Total Liabilities
76.5B
↓ 1.43%
FY18Y/Y Change
Operating Cash Flow
5.9B
↑ 12.61%
Investing Cash Flow
-874.0M
↑ 1224.24%
Financing Cash Flow
-3.5B
↓ 13.29%
FY19Y/Y Change
Operating Cash Flow
8.1B
↑ 35.81%
Investing Cash Flow
-9.8B
↑ 1017.85%
Financing Cash Flow
7.6B
↓ 315.59%
FY20Y/Y Change
Operating Cash Flow
14.1B
↑ 74.19%
Investing Cash Flow
-10.9B
↑ 11.15%
Financing Cash Flow
-1.2B
↓ 115.1%
FY21Y/Y Change
Operating Cash Flow
16.2B
↑ 15.34%
Investing Cash Flow
-538.0M
↓ 95.05%
Financing Cash Flow
-16.2B
↑ 1309.56%
FY22Y/Y Change
Operating Cash Flow
13.1B
↓ 19.38%
Investing Cash Flow
-1.1B
↑ 97.4%
Financing Cash Flow
-17.0B
↑ 4.55%
FY23Y/Y Change
Operating Cash Flow
13.9B
↑ 6.08%
Investing Cash Flow
-2.3B
↑ 116.1%
Financing Cash Flow
-9.4B
↓ 44.49%
Q2 FY23Q/Q Change
Operating Cash Flow
1.9B
↓ 36.46%
Investing Cash Flow
-329.0M
↑ 56.67%
Financing Cash Flow
-2.2B
↓ 28.75%
Q3 FY23Q/Q Change
Operating Cash Flow
4.8B
↑ 151.78%
Investing Cash Flow
-410.0M
↑ 24.62%
Financing Cash Flow
-5.2B
↑ 137.46%
Q4 FY23Q/Q Change
Operating Cash Flow
4.3B
↓ 10.5%
Investing Cash Flow
-1.3B
↑ 228.29%
Financing Cash Flow
967.0M
↓ 118.74%
Q1 FY24Q/Q Change
Operating Cash Flow
2.8B
↓ 33.35%
Investing Cash Flow
-19.6B
↑ 1357.5%
Financing Cash Flow
14.6B
↑ 1414.37%

Technicals Summary

Sell

Neutral

Buy

Bristol-myers Squibb Co. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Bristol-myers Squibb Co.
Bristol-myers Squibb Co.
11.24%
42.75%
18.31%
3.63%
4.81%
Eli Lilly And Company
Eli Lilly And Company
-16.08%
-7.36%
24.44%
185.5%
536.77%
Johnson & Johnson
Johnson & Johnson
-5.19%
5.58%
1.75%
-3.16%
13.11%
Merck & Co. Inc.
Merck & Co. Inc.
-6.33%
-23.41%
-2.64%
20.54%
15.73%
Novo Nordisk A/s
Novo Nordisk A/s
-7.78%
-22.77%
-0.37%
92.7%
273.55%
Abbvie Inc
Abbvie Inc
-6.7%
12.66%
27.61%
49.12%
101.63%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Bristol-myers Squibb Co.
Bristol-myers Squibb Co.
12.66
NA
2.03
0.9
-0.31
0.06
0.04
8.45
Eli Lilly And Company
Eli Lilly And Company
80.9
80.9
0.71
13.16
0.65
0.14
0.01
15.83
Johnson & Johnson
Johnson & Johnson
25.45
25.45
0.92
9.96
0.21
0.08
0.03
29.14
Merck & Co. Inc.
Merck & Co. Inc.
20.89
20.89
0.07
7.74
0.28
0.11
0.03
17.58
Novo Nordisk A/s
Novo Nordisk A/s
34.03
34.03
1.54
22.7
0.89
0.21
0.01
27.07
Abbvie Inc
Abbvie Inc
59.84
59.84
0.41
10.94
0.56
0.08
0.04
3.41
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Bristol-myers Squibb Co.
Bristol-myers Squibb Co.
Hold
$119.4B
4.81%
12.66
-15.3%
Eli Lilly And Company
Eli Lilly And Company
Buy
$711.9B
536.77%
80.9
20.48%
Johnson & Johnson
Johnson & Johnson
Buy
$370.8B
13.11%
25.45
16.74%
Merck & Co. Inc.
Merck & Co. Inc.
Buy
$252.6B
15.73%
20.89
19.23%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$472.8B
273.55%
34.03
35.01%
Abbvie Inc
Abbvie Inc
Buy
$303.5B
101.63%
59.84
9.22%

Insights on Bristol-myers Squibb Co.

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 12.20B → 11.89B (in $), with an average decrease of 2.5% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 1.68B → 1.21B (in $), with an average decrease of 27.9% per quarter

  • Vs ABBV

    In the last 1 year, Abbvie Inc has given 27.6% return, outperforming this stock by 9.3%

  • Vs LLY

    In the last 3 years, Eli Lilly And Company has given 49.1% return, outperforming this stock by 45.5%

Institutional Holdings

  • Vanguard Group Inc

    9.30%

  • BlackRock Inc

    7.82%

  • State Street Corp

    4.51%

  • JPMorgan Chase & Co

    3.68%

  • Charles Schwab Investment Management Inc

    3.01%

  • Morgan Stanley - Brokerage Accounts

    2.58%

Corporate Announcements

  • Bristol-myers Squibb Co. Dividends March,2024

    In the quarter ending March,2024. Bristol-myers Squibb Co. has declared dividend of $0.60

    Read More

Company Information

The Bristol-Myers Squibb Company is an American multinational pharmaceutical company. Headquartered in New York City, BMS is one of the worlds largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.

Organization
Bristol-myers Squibb Co.
Employees
34100
CEO
Dr. Christopher S. Boerner Ph.D.
Industry
Health Technology

FAQs